Largest ever biobank backed by international peer review

The biggest ever biobank has been given the go-ahead by an international panel of experts to begin recruiting 500,000 people in the UK to provide medical data and material.

The green light follows a three-month pilot phase in the Manchester area of England involving 3,800 participants. This initial phase impressed both the funders and the peer reviewers.

"UK Biobank has the potential, in ways that are not currently available elsewhere, to support a wide range of research, particularly investigations into complex interactions of various exposures, including genetic and lifestyle factors in the pathways to disease and health," reads the panel's report on the initiative.

The unique opportunity to build up such a rich set of data justifies the initial establishment costs of GBP 61 million (€89.6 million), the panel agreed. The funding is being provided by the Medical Research Council, the Wellcome Trust, the Department of Health, the Scottish Executive and the North West Regional Development Agency.

Letters can now start going out to men and women aged between 40 and 69, inviting them to attend assessment centres around the UK. Once consent is provided, each participant will be asked to donate a blood and urine sample, have some standard measurements (such as blood pressure) and complete a confidential lifestyle questionnaire. Over the next 20 to 30 years UK Biobank will allow approved researchers to use these resources to study the progression of illnesses such as cancer, heart disease, diabetes and Alzheimer's disease.

Scientists have known for many years that the risk to an individual of developing different diseases can be traced to a complex combination of different factors: lifestyle and environment; personal susceptibility; and luck. Because the Biobank will involve thousands of people with the same disease, it will be able to show more reliably than ever before why some people develop it while others do not. This should help to find new ways to prevent death and disability from many different conditions.

"UK Biobank, already watched with envy by researchers across the world, will provide a remarkable resource, allowing us to answer important questions about health and disease. This study has the opportunity to make a real difference to the health of future generations," said Mark Walport, Director of the Wellcome Trust.

For further information, please visit:
www.ukbiobank.ac.uk

Copyright ©European Communities, 2006
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg – http://cordis.europa.eu.int. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...